How I Treat Patients with Hereditary Antithrombin Deficiency.
Genetic predispositions to venous thromboembolism (VTE) are relatively frequent in the general population and comprise a heterogeneous group of disorders. Whereas the most frequent congenital risk factors for thrombosis only moderately increase the risk, a deficiency in antithrombin (AT), one of the most important natural inhibitors of blood coagulation, carries a higher risk. Congenital AT deficiency is an infrequently encountered genetic risk factor for VTE and different subtypes vary with regard to their thrombotic risk. Patients with congenital AT deficiency, specifically those with quantitative deficiency (type I), may develop thrombosis early in life and often have a conspicuous family history of first-degree and second-degree relatives with VTE. Women are specifically affected because of the risk potentiation by combined estrogen/progestogen oral contraceptives or pregnancy. The lack of controlled trials and even observational studies on large cohorts does not allow therapeutic decisions to be based on scientific evidence. In this review we will discuss cases with thrombotic manifestations and the tailored management of patients with this congenital thrombosis risk factor.